Clinical Trials and Research

A low dose of Vascarta‘s VAS-101, a curcumin-based gel being developed for sickle cell disease (SCD), was well tolerated and showed early signs of reducing red…

For adults with sickle cell disease (SCD), a cost-effectiveness analysis suggests that treatment with nonmyeloablative haploidentical (NMAC-HID) allogeneic stem…

The first patient with sickle cell disease (SCD) treated with the base-editing therapy CS-206 in China remained free of vaso-occlusive crises for over 15…

Children with sickle cell anemia, the most common and severe form of sickle cell disease (SCD), who undergo stem cell transplant experience better long-term…

AbstractSickle cell disease (SCD) is one of the most common inherited blood disorders worldwide. Clinical manifestations are variable, but include hyposplenism,…

SUMMIT, N.J., June 24, 2026 /PRNewswire/ -- Vascarta Inc., a clinical-stage biopharmaceutical company advancing innovative treatments for pain and inflammation,…

Agios Pharmaceuticals’ medication mitapivat rapidly increased levels of the oxygen-carrying protein hemoglobin in patients ages 16 and older with sickle cell…

Mitapivat demonstrated statistically significant improvement in hemoglobin response compared with placebo, with rapid onset and durable effects New analyses…

MITAPIVAT significantly improved haemoglobin levels and markers of haemolysis in patients with sickle cell disease (SCD) in a Phase 3 trial, with additional…

Background:Sickle cell disease (SCD) is a progressive disorder characterized by acute pain crisis (APC), organ damage, and early mortality. Despite the (few)…